Medscape: Do SGLT2 Inhibitors Reduce Risk for Acute Kidney Injury in Patients With Type 2 Diabetes?

RxCowboy

Ranger
Patreon Supporter
Do SGLT2 Inhibitors Reduce Risk for Acute Kidney Injury in Patients With Type 2 Diabetes?
Authors:
News Author: Mitchel L. Zoler, PhD; CME Author: Charles P. Vega, MD
Faculty and Disclosures
CME / ABIM MOC / CE Released: 4/7/2023

Valid for credit through: 4/7/2024

CME / CE Info & Disclosures
Clinical Context
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are known to improve outcomes in chronic kidney disease, even among patients without a history of diabetes, but can they improve the risk for acute kidney injury (AKI)? A previous meta-analysis by Menne and colleagues, which was published in the December 9, 2019 issue of PLOS Medicine,[1] sought an answer to this question.

Researchers found 112 clinical trials and 4 observational studies that examined SGLT2 inhibitors with at least 1 renal outcome. In the prospective trials, the odds ratio (OR) of AKI was 0.64 (95% CI: 0.53, 0.78) in comparing SGLT2 inhibitors and control treatment. Empagliflozin, dapagliflozin, and canagliflozin all appeared to reduce the risk for AKI. In observational studies, the OR for AKI associated with SGLT2 inhibitors was 0.4 (95% CI: 0.33, 0.48).

The current study by Chung and colleagues uses a national database in Taiwan to further analyze the potential value of SGLT2 inhibitors in the prevention of AKI.

Study Synopsis and Perspective
Adults with type 2 diabetes (T2D) treated with an SGLT2 inhibitor had roughly a third fewer episodes of AKI compared with matched people with T2D treated with a dipeptidyl peptidase-4 (DPP-4) inhibitor in an analysis of health insurance data from more than 100,000 Taiwan residents in 2016 to 2018.

The findings added to, and expanded on, prior evidence that treatment with an agent from the SGLT2 inhibitor class cuts the incidence of AKI, said the authors of the report, which was recently published in JAMA Network Open.[2]

The long-term risk for AKI among persons with T2D treated with an SGLT2 inhibitor "appears to be quite low" compared with adults who received an agent from the DPP-4 inhibitor class.

Treatment with an SGLT2 inhibitor -- such as canagliflozin, dapagliflozin, or empagliflozin -- causes a transient drop in kidney function that manifests as a temporary dip in estimated glomerular filtration rate, which caused concerns about AKI when the drugs were first introduced.

Indeed canagliflozin and dapagliflozin had warnings strengthened 7 years ago by the US Food and Drug Administration in a Drug Safety Communication[3] for accumulating reports of AKI linked to their use.

More recent experience has calmed AKI concerns, however.

Commenting on the new study, F. Perry Wilson, MD, a nephrologist at Yale School of Medicine in New Haven, Connecticut, said, "It's a nice piece of data to demonstrate that the long-term risk from SGLT2 inhibitor treatment is low."

Wilson was not involved with the new study.

The Taiwan study found a cumulative incidence of AKI events during about 2.5 years of follow-up of 5.55 events/1000 patient-years (PY) among adults with T2D receiving an SGLT2 inhibitor and 7.88 events/1000 PY among persons taking a DPP-4 inhibitor, such as sitagliptin.

Main Barrier to SGLT2 Inhibitor Use Is Unfamiliarity, Not AKI Risk
"My impression is that the main barrier to wider use of the SGLT2 inhibitor class is not a perceived risk for causing AKI, but rather ongoing unfamiliarity with the class," said Wilson in an interview.

Although he sees "relatively broad comfort with and enthusiasm for the class among nephrologists and cardiologists," routine prescribing does not seem to have caught on nearly as much among primary care physicians, he said.

Clinicians in primary care "still perceive the SGLT2 inhibitor class as something of a 'specialty drug,' and they defer initiating it on that basis," Wilson observed. "That's probably not a good thing," as many people with [T2D] do not have access to a specialized clinician who might be more amenable to prescribing an SGLT2 inhibitor.

One example of the lag in SGLT2 inhibitor uptake for people with T2D in practice was a recent report from the Centers for Disease Control and Prevention (CDC) published in the Annals of Internal Medicine.[4] Researchers identified a representative US sample of 1330 adults with T2D studied in depth in 2017 to 2020, of whom 82% fulfilled criteria published in 2022[5] for receiving treatment with an SGLT2 inhibitor. Despite this high prevalence of medical appropriateness, a scant 5.3% of persons with a recommended indication actually received an agent from this class.[4]

Early AKI Concern Has Diminished
Results from more recent studies, such as a 2019 meta-analysis[1] of more than 100 randomized studies and 4 large observational studies that together included about 180,000 people receiving SGLT2 inhibitor treatment, showed the opposite of SGLT2 inhibitor treatment triggering AKI.

In the trials, people taking an SGLT2 inhibitor had a relative 25% lower rate of AKI events, whereas in the observational studies, SGLT2 inhibitor treatment was linked with a 60% relative reduction in AKI. The study also found that SGLT2 inhibitor use in the trials was linked with a significant 20% relative increase in the incidence of low fluid volume.

Despite accumulated evidence exonerating AKI risk, US labels for canagliflozin, dapagliflozin, and empagliflozin continue to cite AKI as a potential adverse reaction, especially in patients who undergo volume depletion while on SGLT2 inhibitor treatment.

The new Taiwan study[2] used data from the country's National Health Insurance Research Database.[6] Of more than 250,000 adults with T2D in the system from May 2016 to December 2018, the researchers identified 52,231 propensity-score matched pairs of people where one was on treatment with an SGLT2 inhibitor and the other with a DPP-4 inhibitor.[2]

During follow-up, 856 (0.8%) of these persons had an AKI event, including 102 people with AKI that required dialysis (AKI-D).

A logistic regression analysis that adjusted for 16 potential confounders showed that SGLT2 inhibitor treatment was linked to a significant 34% reduction in AKI events compared with DPP-4 inhibitor treatment, as well as to a significant 44% relative risk reduction in the incidence of AKI-D, reported the authors from several medical institutions in Taiwan.

The study's main limitation was its reliance on "quite insensitive" administrative coding data to identify AKI cases, commented Wilson.

He also noted that although concern about AKI events secondary to SGLT2 inhibitor treatment is uncommon among US clinicians, they do worry about the potential risk for fungal infections, urinary tract infection, or gangrene in people with diabetes who receive an agent from this class.

The study received no commercial funding, and none of the authors had disclosures. Wilson has reported relevant financial relationships.
 
Study Highlights
  • Investigators drew study data from the Taiwan National Health Insurance Database. They conducted a retrospective cohort study using diagnostic codes recorded between 2016 and 2018 in the database.
  • The primary study outcomes were AKI and AKI-D. Researchers compared adults with T2D receiving SGLT2 inhibitors or DPP-4 inhibitors in this outcome. Researchers compared pairs of patients according to demographic factors such as age and sex.
  • Researchers also performed an analysis comparing the 2 drugs in the prevention of AKI in typical acute conditions. Such as respiratory failure and sepsis.
  • The study analysis accounted for comorbid illnesses as well as the use of multiple other medications.
  • The researchers compared 52,231 pairs of patient records for study outcomes. 44.1% of the cohort was female, and the mean age was 58 ± 12 years. Nearly 99% of patients receiving SGLT2 inhibitors were taking SGLT-2 inhibitors or DPP-4 inhibitors. Those patients taking dapagliflozin were younger and had fewer comorbidities compared with the empagliflozin cohort.
  • 0.8% of patients developed AKI during the study period, and < 0.1% had AKI-D.
  • The cumulative incident rates of AKI in the SGLT2-inhibitor and DPP-4--inhibitor cohort were 5.55 and 7.88 cases per 1000 PY, and the cumulative incident rates of AKI-D in the SGLT2-inhibitor and DPP-4 inhibitor cohort were 0.60 and 1.00 cases per 1000 PY.
  • The adjusted hazard ratio (aHR) for AKI in comparing SGLT2 inhibitors vs DPP-4 inhibitors was 0.66 (95% CI: 0.57, 0.75). The respective HR for AKI-D was 0.56 (95% CI: 0.37, 0.84).
  • SGLT2 inhibitors were protective against AKI regardless of the presence of other treatments, such as aspirin or statins. There was an insignificant improvement in the risk for AKI among patients using both SGLT2 inhibitors and metformin vs metformin alone.
  • Specifically, SGLT2 inhibitors were significantly associated with reductions in the risk for AKI in the settings of respiratory failure (HR 0.42 [95% CI: 0.26, 0.69]) and shock (HR 0.48 [95% CI: 0.23, 0.99]), but SGLT2 inhibitors had insignificant results for AKI related to heart disease and sepsis.
  • The risk for progression to stage IV chronic kidney disease or worse in the time around hospitalization was reduced by 6.53% in the SGLT2 inhibitor vs DPP-4 inhibitor groups (P = .045).
Clinical Implications
  • A previous meta-analysis found that SGLT2 inhibitors were associated with lower risks for AKI in both clinical trials and observational studies. Empagliflozin, dapagliflozin, and canagliflozin all appeared to reduce the risk for AKI.
  • The current study by Chung and colleagues comparing SGLT2 inhibitors and DPP-4 inhibitors among adults with diabetes found that SGLT2 inhibitors can reduce the risk for AKI and AKI-D. Specifically, SGLT2 inhibitors were significantly associated with reductions in the risk for AKI in the settings of respiratory failure and shock, but SGLT2 inhibitors had insignificant results for AKI related to heart disease and sepsis.
  • Members of the healthcare team should become familiar with the mechanism of action and potential adverse events of SGLT2 inhibitors in order to facilitate shared decision-making discussions with patients who have Type 2 diabetes.
 
This class of medications also reduces risk of cardiovascular death or heart failure, in diabetics or non-diabetics. We don't know exactly how they do that. But it is very, very useful in the VA population. I use the hell out of them. The drawback, they are incredibly expensive which amazes me that they are on the VA formulary. The other drawback, the basic way they work is they inhibit an enzyme in the kidney which basically causes the patient to pee out more sugar, which makes the urine a good growth medium for bacteria and yeast, increasing the risk of urinary tract and yeast infection. It is a much higher risk in females than in males, and in males it tends to manifest in rash in the groin area... jock itch. I've had this discussion with a cardiologist, decrease in CV risk versus jock itch... "treat the damn jock itch!" Well, duh. I mean, it kind of cuts against my grain as a pharmacist to chronically treat an adverse drug effect, but we do it with other things all the time... hypokalemia and diuretics... it's just that with skin rashes stopping the drug is almost always an automatic thing, but this rash is not an allergic reaction.

Protection against acute kidney injury, chronic kidney disease, protection against heart failure and cardiovascular death... usually when I tell patients about the added benefits of Jardiance they say, "Sure, I'll try it."
 
What are your thoughts on low dose rapamycin as a lifespan/healthspan promoter? It looks like there are a few studies exploring it.
 
What are your thoughts on low dose rapamycin as a lifespan/healthspan promoter? It looks like there are a few studies exploring it.
Sirolimus is a potent immune suppressant. Not sure why anyone would want to take it to try to promote health as it would actually promote opportunistic infections. What studies?
 
Sirolimus is a potent immune suppressant. Not sure why anyone would want to take it to try to promote health as it would actually promote opportunistic infections. What studies?
The dose is apperantly lower, where it is not nearly as strong as of an immune supressant and only inhibits mTORC1 and not mTORC2, unlike the typical dose used for implant rejection, etc. This low dose is also pulsed and only perscribed once a week to reduce the chance of side effects:

Overview of research

TRIAD Trial on Dog Longevity

Human Trial
 
Last edited:
The dose is apperantly lower, where it is not nearly as strong as of an immune supressant and only inhibits mTORC1 and not mTORC2, unlike the typical dose used for implant rejection, etc. This low dose is also pulsed and only perscribed once a week to reduce the chance of side effects:

Overview of research

TRIAD Trial on Dog Longevity

Human Trial

I will have to look at the animal studies. I am very interested in the heart failure study. We have no treatments specifically for HFpEF.


Sent from my iPhone using Tapatalk
 
200.webp
 
Back
Top